Market Overview:
The global PPIs medication market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of gastrointestinal disorders, rising geriatric population, and growing demand for over-the-counter (OTC) PPIs medications. Based on type, the global PPIs medication market is segmented into dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. Esomeprazole is expected to be the fastest growing segment during the forecast period owing to its high efficacy and safety profile. Based on application, the global PPIs medication market is segmented into hospital pharmacy, retail pharmacy and other applications such as research laboratories and food industry. The hospital pharmacy segment accounted for majority of share in 2017 due to high utilization rates for hospitalized patients suffering from various gastrointestinal disorders such as GERD (gastroesophageal reflux disease), peptic ulcer disease (PUD), Barrett’s esophagus and Zollinger-Ellison syndrome (ZES). However, with increasing awareness about OTC availability of these drugs among consumers coupled with easy accessibility through retail pharmacies across regions; this scenario is likely to change in coming years.
Product Definition:
PPIs (proton pump inhibitors) are a class of drugs that reduce the production of stomach acid. They are used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. PPIs are important because they can help to heal ulcers and improve symptoms in people with GERD.
Dexlansoprazole:
Dexlansoprazole (Dexilant) is a non-competitive, non-nucleoside analog of lansoprazole. It is used as an antiemetic in the treatment of cancer and to prevent nausea and vomiting associated with cancer therapy. Dexlansoprazole has been approved by the U.S Food and Drug Administration (FDA) for use in patients who have completed chemotherapy for cancer that exhibited chemo-sensitive adverse effects during previous therapy cycles.
Esomeprazole:
Esomeprazole is a widely prescribed medication for the treatment of heartburn and related symptoms. It is also used as an anti-inflammatory drug to reduce swelling and redness caused by allergies or reactions to medications. In addition, it can be used for the treatment of ulcers, cancer-related nausea & vomiting, and maintenance therapy after surgery.
Application Insights:
Based on application, the globalPPIs medication market is segmented into hospital pharmacy, retail pharmacy and others. Hospital pharmacies dominated the overall industry in terms of revenue share in 2017 owing to factors such as an increase in healthcare expenditure globally and growing awareness about PPI therapy among patients.
The retail pharmacies are expected to grow at a lucrative rate over the forecast period due to increasing consumer preference for cost-effective medicines with high availability across retailers¢â‚¬â„¢ stores. Moreover, rising demand for PPIs from individuals who have difficulty accessing or afford prescription drugs due to financial constraints will further boost growth during this period. Other applications include clinics/dentists offices and other non-retail pharmacies.
Regional Analysis:
Europe dominated the global market in 2017 owing to high incidence of gastric cancer and other diseases. Asia Pacific is expected to be the fastest-growing regional market during the forecast period due to increasing awareness about PPIs, rising disposable income, and improving healthcare facilities in emerging countries such as China and India. In addition, growing medical tourism industry will drive demand for PPIs medication in APAC region over the forecast period.
Moreover, availability of generic drugs for off-label use may further increase growth potential of this region. For instance, esomeprazole is available OTC as a treatment for ulcers caused by HIC (Hirschsprung's disease). Moreover it has been reported that omeprazole is used OTC for treatment of HIC (reflux esophagitis) caused by Group A streptococcus infections among children under two years old in Japan’s Kinki Region.
Growth Factors:
- Increasing incidence of gastrointestinal diseases: The incidence of gastrointestinal diseases is increasing globally, which is driving the demand for PPIs.
- Growing awareness about the benefits of PPIs: There is growing awareness among patients and healthcare professionals about the benefits of using PPIs, which is propelling their demand.
- Rising prevalence of Helicobacter pylori infection: The prevalence of Helicobacter pylori infection is rising globally, and this is leading to an increase in the use of PPIs for its treatment.
- Growing geriatric population: The global geriatric population is growing rapidly, and this is resulting in an increase in the number of people who are susceptible to gastrointestinal diseases and require PPI therapy.
Scope Of The Report
Report Attributes
Report Details
Report Title
PPIs Medication Market Research Report
By Type
Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole
By Application
Hospital Pharmacy, Retail Pharmacy, Other
By Companies
Takeda, Pfizer, AstraZeneca, Bayer, Sun Pharma, Teva, Eisai Co., Mylan, AOSAIKANG Pharma, Luoxin Pharma, LIVZON, Eastchina Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global PPIs Medication Market Report Segments:
The global PPIs Medication market is segmented on the basis of:
Types
Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
- Pfizer
- AstraZeneca
- Bayer
- Sun Pharma
- Teva
- Eisai Co.
- Mylan
- AOSAIKANG Pharma
- Luoxin Pharma
- LIVZON
- Eastchina Pharma
Highlights of The PPIs Medication Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Dexlansoprazole
- Esomeprazole
- Lansoprazole
- Omeprazole
- Pantoprazole
- Rabeprazole
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PPIs Medication Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PPIs are medications that are used to treat heartburn and other stomach problems. PPIs work by blocking the action of acid in the stomach.
Some of the major players in the ppis medication market are Takeda, Pfizer, AstraZeneca, Bayer, Sun Pharma, Teva, Eisai Co., Mylan, AOSAIKANG Pharma, Luoxin Pharma, LIVZON, Eastchina Pharma.
The ppis medication market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 PPIs Medication Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 PPIs Medication Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 PPIs Medication Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the PPIs Medication Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global PPIs Medication Market Size & Forecast, 2020-2028
4.5.1 PPIs Medication Market Size and Y-o-Y Growth
4.5.2 PPIs Medication Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Dexlansoprazole
5.2.2 Esomeprazole
5.2.3 Lansoprazole
5.2.4 Omeprazole
5.2.5 Pantoprazole
5.2.6 Rabeprazole
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global PPIs Medication Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 PPIs Medication Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Dexlansoprazole
9.6.2 Esomeprazole
9.6.3 Lansoprazole
9.6.4 Omeprazole
9.6.5 Pantoprazole
9.6.6 Rabeprazole
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Dexlansoprazole
10.6.2 Esomeprazole
10.6.3 Lansoprazole
10.6.4 Omeprazole
10.6.5 Pantoprazole
10.6.6 Rabeprazole
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Dexlansoprazole
11.6.2 Esomeprazole
11.6.3 Lansoprazole
11.6.4 Omeprazole
11.6.5 Pantoprazole
11.6.6 Rabeprazole
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Dexlansoprazole
12.6.2 Esomeprazole
12.6.3 Lansoprazole
12.6.4 Omeprazole
12.6.5 Pantoprazole
12.6.6 Rabeprazole
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Dexlansoprazole
13.6.2 Esomeprazole
13.6.3 Lansoprazole
13.6.4 Omeprazole
13.6.5 Pantoprazole
13.6.6 Rabeprazole
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 PPIs Medication Market: Competitive Dashboard
14.2 Global PPIs Medication Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda
14.3.2 Pfizer
14.3.3 AstraZeneca
14.3.4 Bayer
14.3.5 Sun Pharma
14.3.6 Teva
14.3.7 Eisai Co.
14.3.8 Mylan
14.3.9 AOSAIKANG Pharma
14.3.10 Luoxin Pharma
14.3.11 LIVZON
14.3.12 Eastchina Pharma
